anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Glipizide tablets are indicated as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory.

In initiating treatment for non-insulin-dependent diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified, and corrective measures taken where possible.

If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered. Use of glipizide must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone also may be transient, thus requiring only short-term administration of glipizide.

During maintenance programs, glipizide should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Judgements should be based on regular clinical and laboratory evaluations.

In considering the use of glipizide in asymptomatic patients, it should be recognized that controlling the blood glucose in non-insulin-dependent diabetes has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes.
An aerosol dispersing agent in which the active ingredients of an aerosol can be dispersed comprises a propellant and a solution of lecithin and/or lanolin and/or cholesterol and/or a derivative of lanolin or cholesterol in an ester of an aliphatic acid, the acid radical of which contains 8 to 18 carbon atoms and the alcohol residue of which contains 2 to 8 carbon atoms. The preferred ester is isopropyl myristate; others include ethyl palmitate, ethyl laurate, n-amyl stearate and ethyl caprylate. Other organic solvents may be present.  Hydrogenated lanolins, polyoxyethylene derivatives of lanolin and aliphatic acid esters of cholesterol are the specified derivatives.  The propellant is an alkane containing 3, 4 or 5 carbon atoms, an alkyl chloride containing 1, 2 or 3 carbon atoms or a fluoro-chloro-alkane containing 1, 2 or 3 carbon atoms.  The preparation may be a cosmetic or medicine e.g. containing antibiotics or steroids.
The invention relates to a preparing technology of a new anti-anaphylaxis medicament-Setastine hydrochloride, pertaining to the field of chemical medicines. N-(2-chloroethyl)-nitrogen-heterocyclic heptane hydrochloride is neutralized by NaOH and then carries out condensation reaction with p-dichlorobenzene alcohol. During the synthesis of the Setastine hydrochloride, dimethyl benzene is adopted as a dissolvent, and potassium iodide and polyethyleneglycol 400 are adopted as catalysts. The synthesis technology of the Setastine hydrochloride improves the defects of overseas production technologies, which not only reduces the toxicity of solvents, but also greatly shortens the reaction time. Meanwhile, the synthesis technology greatly improves the production yield and production efficiency, with a total yield of 50 percent to 60 percent which is far more than the yield of 30 percent in the overseas production technologies. Furthermore, the product quality fully meets the requirements of national standards.
Viral diseases pose a significant threat to tomato crops (Solanum lycopersicum L.), one of the world's most economically important vegetable crops. The limited genetic diversity of cultivated tomatoes contributes to their high susceptibility to viral infections. To address this challenge, tomato breeding programs must harness the genetic resources found in native populations and wild relatives. Breeding efforts may aim to develop broad-spectrum resistance against the virome. To identify the viruses naturally infecting 19 advanced lines, derived from native tomatoes, high-throughput sequencing (HTS) of small RNAs and confirmation with PCR and RT-PCR were used. Single and mixed infections with tomato mosaic virus (ToMV), tomato golden mosaic virus (ToGMoV), and pepper huasteco yellow vein virus (PHYVV) were detected. The complete consensus genomes of three variants of Mexican ToMV isolates were reconstructed, potentially forming a new ToMV clade with a distinct 3' UTR. The absence of reported mutations associated with resistance-breaking to ToMV suggests that the Tm-1, Tm-2, and Tm-22 genes could theoretically be used to confer resistance. However, the high mutation rates and a 63 nucleotide insertion in the 3' UTR, as well as amino acid mutations in the ORFs encoding 126 KDa, 183 KDa, and MP of Mexican ToMV isolates, suggest that it is necessary to evaluate the capacity of these variants to overcome Tm-1, Tm-2, and Tm-22 resistance genes. This evaluation, along with the characterization of advanced lines using molecular markers linked to these resistant genes, will be addressed in future studies as part of the breeding strategy. This study emphasizes the importance of using HTS for accurate identification and characterization of plant viruses that naturally infect tomato germplasm based on the consensus genome sequences. This study provides crucial insights to select appropriate disease management strategies and resistance genes and guide breeding efforts toward the development of virus-resistant tomato varieties.
Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory condition often complicated by cardiovascular disease (CVD) due to shared inflammatory pathways. This review explores the cardiovascular impacts of emerging anti-inflammatory therapies in COPD. Phosphodiesterase (PDE) inhibitors may offer anti-inflammatory effects with improved lung function but pose potential risks for arrhythmias when PDE3 is inhibited although PDE4 inhibitors reduce cardiovascular events by improving endothelial function and reducing thrombosis. Similarly, p38 mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) inhibitors target COPD-related inflammation and may benefit COPD patients with CVD. p38 MAPK inhibitors reduce cardiac fibrosis, enhance contractility and lower the risk of arrhythmia. PI3K inhibitors target the PI3K/Akt pathway, which drives atherosclerosis and cardiac fibrosis, and thus potentially mitigate both plaque instability and fibrosis. Biologic therapies, including monoclonal antibodies that inhibit IL-5, IL-13/IL-4, thymic stromal lymphopoietin, IL-33, and IL-17A, show promise in reducing exacerbations but require close cardiovascular monitoring due to their immunomodulatory effects. Single-target inhibitors of neutrophil elastase or matrix metalloproteinases show limited efficacy in COPD but may aid cardiovascular patients by stabilizing atherosclerotic plaques through promoting vascular smooth muscle cell proliferation. However, their tendency to degrade the extracellular matrix and attract immune cells may heighten plaque rupture risk, contraindicating use in CVD. Alpha-1 antitrypsin replacement therapy holds promise, potentially reducing COPD exacerbations and providing cardiovascular protection, especially in myocardial injury. Understanding the influence of these innovative therapies on CVD is vital, making it imperative to examine these molecules in COPD patients with CVD at an early stage.
The invention discloses a method for microwave reflux extraction of general flavone in walnut peel residue. In the method, alcohol solvent is used for extraction by a microwave reflux extraction method. Preferentially, walnut epicarp (peel) residue which is higher in general flavone content and convenient to obtain is taken as a raw material for extraction. The method comprises the steps of: mixing the walnut peel with the average grain diameter of 50 meshes and 50% of alcohol according to the proportion, extracting under the condition that the microwave power series is 150W, carrying out suction filtering, and washing filter residue by solvent to obtain leaching liquid of the general flavone; collecting all solution, and carrying out rotary evaporation concentration under reduced pressure to obtain the product; and finally, measuring all indexes. According to the invention, the extraction rate of the general flavone is 86.73%, and the purity of the general flavone is 39.93%. The method is fast and high in extraction rate, simple in equipment operation, low in energy consumption, less in solvent dosage, and easy in solvent recovery and is suitable for the expanded production of a factory. The extracted general flavone is wide in application, has the functions of antibacterium, anticancer, anti-tumor, anti-inflammation, analgesia and the like, thus having wide application prospect in the aspects of medicine, food and the like.
Purpose: To analyze the related factors of portal vein thrombosis (PVT) after hepatectomy. Methods: A retrospective analysis was made on 1029 patients who underwent partial hepatectomy in the first affiliated Hospital of Chongqing Medical University from March 2018 to March 2023, including PVT group (n = 24) and non-PVT group (n = 1005). The general and clinical data of the two groups were collected. Univariate and multivariate logistic regression analysis was used to analyze the clinical information of the two groups. Result: The proportion of preoperative hepatitis B, liver cirrhosis, ascites, intraoperative blood transfusion, postoperative hemostatic drugs, preoperative prothrombin time, intraoperative portal occlusion time, operation time, international standardized ratio of prothrombin time on the first day after operation, D-dimer on the first day after operation, fibrin degradation products on the first day after operation and postoperative hospital stay in the PVT group were all higher than those in the control group (P < .05). The preoperative platelet and albumin in the PVT group were lower than those in the control group. Intraoperative blood transfusion, liver cirrhosis, ascites, international standardized ratio of postoperative prothrombin time, postoperative fibrin degradation products, hilar occlusion time and albumin were independent risk factors for PVT. Conclusion: There are many influencing factors of PVT after hepatectomy. Clinical intervention should be taken to reduce PVT. Clinical Registration Number: K2023-348.
523,594. Coating medicines. LIPOWSKI, I. Nov. 5, 1938, No. 32135. Convention date, May 2, 1938 [A Specification was laid open to inspection under Sect. 91 of the Acts, May 25, 1939.] [Class 81 (i)] Pills, pastilles &c. are coated with material comprising a solution of rubber in benzene. Xylene may be added to retard evaporation of the solution which may be applied by an air blast. According to the Specification as open to inspection under Sect. 91 pills, etc. coated with various materials largely of known kind and of varying degrees of permeability or solubility are assembled in groups portions of which may be mixed together to provide for a graduated dosing effect. Coating substances specified include cellulose ethers and esters with fatty or waxy softening agents, a mixture of keratin, gluten, graphite and animal charcoal, a mixture of cocoa butter, stearic acid and paraffin, a mixture of tolu balsam and collodion, a mixture of dammar, sandarac and mastic resins. This subject-matter does not appear in the Specification as accepted.
The present invention relates to a novel rotavirus J19, a cultivating method and the application thereof in medical science. Samples of patient excrement containing novel RV are acted by high-concentration trypsin (100 mu g/ml) at the temperature of 37 DEG C for one hour to be additionally added with serum-free DMEM containing the trypsin (100 mu g/ml) after being inoculated in PHEK cells to be adsorbed for one hour at the temperature of 37 DEG C, the samples, the high-concentration trypsin and the serum-free DMEM are cultivated for 3 hours by revolving a drum at the temperature of 37 DEG C to obtain a cell cultivating solution frozen and melted for one time to be used as an inoculum for cultivating next generations, and the cell cultivating solution is cultivated to pass the generations. The cell cultivating solution is checked on viral nucleic acid, antigen and forms by PAGE, IF, EM and IEM, one stain of rotavirus is cultivated and separated from 10 portions of excrement samples in a result, and the rotavirus is named as J19. The rotavirus can be stably cultivated on PHEK cells to pass the generations, and a viral nucleic acid (dsRNA) electrophoretic pattern of the rotavirus is completely the same as a dsRNA electrophoretic pattern in the excrement samples initially used for inoculation and is obviously different from dsRNA electrophoretic patterns in RV of A, B and C groups. The rotavirus J19 does not belong to RV of the A , B and C groups and is novel RV. The rotavirus J19 is preserved at the ordinary Microbe Center of CMSPC in October. 29, 2001, and the preservation number is CGMCC No. 0647.
The present invention includes a Myogenic vector system (MVS) for the expression of a nucleic acid sequence in myogenic tissue. The MVS contains a promoter, a cassette with the sequence of interest, a 3' untranslated region (3' UTR) and contiguous noncoding region (NCR). Further enhancements can include the addition of a leader sequence, intron sequence, initiation codon and specific restriction endonucleases. To facilitate uptake and myogenic expression, the MVS can be coated with histones and a DNA initiation complex composed of a serum response factor, transcription initiation factor and a transregulatory factor attached to the promoter by interaction with the serum response element and TATA box. The MVS can be used for a variety of purposes including gene replacement, vaccine production, vaccination, treatment of disease and muscle atrophy. When the MVS is injected into a myogenic system it will produce the polypeptide from the sequence of interest.
Provided is a traditional Chinese medicine preparation for treating heart diseases and a preparation method therefor. The traditional Chinese medicine preparation is prepared from the following raw materials which are made into active ingredients. The raw materials comprise, by weight, 25-40 parts of giant salamander bone and meat powder, 3-8 parts of giant salamander internal organ powder, 10-25 parts of donkey-hide gelatin, 10-25 parts of bletilla striata, 10-18 parts of radix rehmanniae, 15-25 parts of Chinese angelica, 20-30 parts of white peony root and 15-30 parts of ligusticum chuanxiong hort. The preparation method comprises steps: (1) giant salamanders with bones are steamed, dried and crushed to obtain the giant salamander bone and meat powder; (2) livers, spleens and stomachs of internal organs of the giant salamanders are dried at a low temperature, crushed and ground to powder; (3) the radix rehmanniae, the Chinese angelica, the bletilla striata, the white peony root and the ligusticum chuanxiong hort are added into water, boiled over high heat, decocted over gentle heat for 30-40 min and filtered, the weight ratio of the materials to the water is 1:2-3; (4) the substances obtained from step (1), step (2) and step (3) are added into the donkey-hide gelatin and then decocted over gentle heat for 12-26 min. The traditional Chinese medicine preparation is used to treat heart diseases. The traditional Chinese medicine preparation is mild and advantaged by rapid effect, high effective rate and minimal side effects.
The safety and efficacy of Rapamune as immunosuppressive therapy have not been established in liver transplant patients; therefore, such use is not recommended. The use of Rapamune has been associated with adverse outcomes in patients following liver transplantation, including excess mortality, graft loss and hepatic artery thrombosis (HAT).

In a study in de novo liver transplant patients, the use of Rapamune in combination with tacrolimus was associated with excess mortality and graft loss (22% in combination versus 9% on tacrolimus alone). Many of these patients had evidence of infection at or near the time of death.

In this and another study in de novo liver transplant patients, the use of Rapamune in combination with cyclosporine or tacrolimus was associated with an increase in HAT (7% in combination versus 2% in the control arm); most cases of HAT occurred within 30 days post-transplantation, and most led to graft loss or death.

In a clinical study in stable liver transplant patients 6–144 months post-liver transplantation and receiving a CNI-based regimen, an increased number of deaths was observed in the group converted to a Rapamune-based regimen compared to the group who was continued on a CNI-based regimen, although the difference was not statistically significant (3.8% versus 1.4%) [see Clinical Studies (14.5)].
Patients with locally advanced non-small-cell lung cancer treated with radiotherapy alone or in combination with chemotherapy with curative intent. Patients are included before initiation of the treatment. A Cardiac MR and ECG are performed at the beginning of the treatment, and at 6, 12, and 24 months after radiotherapy.
People on low-incomes in the UK develop multiple long-term health conditions over 10 years earlier than affluent individuals. Financial diaries -new to public health- are used to explore the lived experiences of financially-vulnerable individuals, diagnosed with at least one long-term condition, living in two inner-city London Boroughs. Findings show that the health status of these individuals is a key barrier to work opportunities, undermining their income. Their precarious and uncertain financial situation, sometimes combined with housing issues, increased stress and anxiety which, in turn, contributed to further deteriorate participants' health. Long-term health conditions limited the strategies to overcome moments of financial crisis and diarists frequently used credit to cope. Restrictions to access reliable services and timely support were connected to the progression of multiple long-term conditions. Models that integrate healthcare, public health, welfare and financial support are needed to slow down the progression from one to many long-term health conditions.
Ovariohysterectomy is a common surgical procedure in pet rabbits and one of its potential complications is postoperative gastrointestinal stasis, possibly exacerbated by prolonged surgery time. The objective of this prospective clinical study was to compare two techniques for surgical haemostasis with respect to procedural duration, postoperative pain, and return of gastrointestinal function, in 22 female rabbits undergoing ovariohysterectomy. Rabbits were assigned to one of two groups: conventional vessel ligation (CVL) and haemostasis with a vessel sealing device (VSD). The outcome variables for comparison between the two groups, recorded at 60-, 120-, 180-, and 360-minutes post anaesthesia, were duration of anaesthesia and surgery, postoperative Rabbit Grimace Scale scores, and measured food intake and faecal output. The vessel sealing device caused no appreciable blood loss. The duration of both surgery and anaesthesia was shorter in group VSD (20 ± 4 and 31 ± 6 minutes, respectively) than in group CVL (43 ± 9 and 54 ± 9 minutes, respectively) (p < 0.001). There were no differences between groups in time elapsed from the end of anaesthesia to both first food intake and first defecation. In both groups, the score of the Rabbit Grimace Scale decreased over time with statistically significant differences between 60 minutes and all the subsequent time points (p < 0.001). Vessel sealing devices may be recommended over conventional haemostasis for rabbit ovariohysterectomy to decrease the duration of surgery and anaesthesia, with potential beneficial effects on sustainability and practice workflow.
Methods, systems, and kits for subcutaneously implanting articles, such as drug inserts and reservoirs. The methods rely on percutaneously forming a tissue tract and radially dilating the tract to a diameter which permits introduction of the article. By fully expanding the lumenal diameter of the tissue tract prior to introduction of the article, damage to the article resulting from passage through a partially expanded tissue tract can be avoided. In the exemplary embodiment, a radially expandable sleeve is first percutaneously introduced to the subcutaneous target site. An assembly of a cannula and dilator is then passed through the sleeve, effecting radial expansion. The dilator is removed and the article is then introduced through a lumen of the cannula.
The prescriber should ensure that the patient is fully aware of the correct method of therapy and identify which specific warts should be treated.

Apply twice daily for 3 consecutive days, then discontinue for 4 consecutive days. This one-week cycle of treatment may be repeated until there is no visible wart tissue or for a maximum of four cycles. If there is incomplete response after four treatment cycles, discontinue treatment and consider alternative treatment. Safety and effectiveness of more than four treatment cycles has not been established. There is no evidence to suggest that more frequent application will increase efficacy, but additional applications would be expected to increase the rate of local adverse reactions and systemic absorption.

Condylox Gel 0.5% should be applied to the warts with the applicator tip or finger. Application on the surrounding normal tissue should be minimized. Treatment should be limited to 10 cm2 or less of wart tissue and to no more than 0.5 gram of the gel per day.

Care should be taken to allow the gel to dry before allowing the return of opposing skin surfaces to their normal positions. Patients should be instructed to wash their hands thoroughly before and after each application.
Anti-multiple myeloma B cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies represent a promising treatment strategy with high response rates in myeloma. However, durable cures following anti-BCMA CAR-T cell treatment of myeloma are rare. One potential reason is that a small subset of minimal residual myeloma cells seeds relapse. Residual myeloma cells following BCMA-CAR-T-mediated treatment show less-differentiated features and express stem-like genes, including CD24. CD24-positive myeloma cells represent a large fraction of residual myeloma cells after BCMA-CAR-T therapy. In this work, we develop CD24-CAR-T cells and test their ability to eliminate myeloma cells. We find that CD24-CAR-T cells block the CD24-Siglec-10 pathway, thereby enhancing macrophage phagocytic clearance of myeloma cells. Additionally, CD24-CAR-T cells polarize macrophages to a M1-like phenotype. A dual-targeted BCMA-CD24-CAR-T exhibits improved efficacy compared to monospecific BCMA-CAR-T-cell therapy. This work presents an immunotherapeutic approach that targets myeloma cells and promotes tumor cell clearance by macrophages.